4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.
Level 5 - mechanism / opinion, no new human data
Mechanistic reasoning and narrative review with no primary empirical human data reported in the abstract
PubMed 32824985 · doi:10.3390/ijms21175953
What was done
The authors examined the mechanistic potential of 4,4'-diaminodiphenyl sulfone (DDS, dapsone) to act as an inflammasome competitor. The paper discusses TLR-mediated activation of the NLRP3 inflammasome, the role of TLR genetic polymorphisms (such as TLR2 Arg677Trp in Korean patients with lepromatous leprosy), and the potential preventative mechanisms of DDS across conditions including Hansen's disease, Alzheimer's disease, and SARS-CoV-2 infection.
What was found
No quantitative data, sample sizes, or effect estimates are reported in the abstract. The authors report descriptively that of three tested antibiotics, DDS was effective in regulating molecular activators of the NLRP3 inflammasome linked to mild cognitive impairment, Parkinson's disease, and Alzheimer's disease, suggesting it functions as an inflammasome competitor.
Why it matters
The paper presents a mechanistic hypothesis for repurposing dapsone as an anti-inflammatory modulator targeting NLRP3 activation across viral infections and neurodegenerative diseases.
Limits
The abstract contains no empirical trial design, sample size, control comparisons, or quantitative metrics. Evidence is based entirely on mechanistic and narrative claims without directly demonstrated clinical efficacy.
Cited by
- supports Dapsone penetrates the brain and inhibits NLRP3 inflammasomes.